PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
Globe Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤Cretostimogene reduced recurrence risk 68%, with hazard ratio 0.32 and p<0.0001
- ➤PIVOT-006 enrolled 133 patients with intermediate-risk and high-grade Ta NMIBC
- ➤Two-year recurrence-free survival reached 81.9% for cretostimogene versus 56.2% surveillance
- ➤CG Oncology plans BLA submission in 2027 for intermediate-risk and high-grade Ta NMIBC
– Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001)
– Compelling safety and tolerability results, no Grade 3 or higher TRAEs and no treatment-related discontinuations
Get started
Create a free account to read the full story.
